AHR and cancer: With the goal of identifying AhR ligands that inhibit cancer growth and exhibit favorable toxicity profiles, we previously screened Food and Drug Administration-approved drugs and identified raloxifene as an AhR ligand with pro-apoptotic effects in triple-negative breast cancer (TNBC) cells [9], and further studies have identified a novel raloxifene analog with a more favorable toxicity profile than the parent molecule [145].